Respiratory Conditions

COPD (Chronic Obstructive Pulmonary Disease)

COPD is a common, progressive and life-threatening lung disease that is usually caused by cigarette smoke, air pollution, and gases1. COPD encompasses conditions such as chronic bronchitis (airway inflammation with thick mucus) and emphysema (damage in the lung’s air sacs), which contribute to symptoms like chronic cough, sputum production, wheezing, and breathlessness1. In the U.S., there are >15 million diagnosed cases, with prevalence rising in older adults, and an estimated 12 million undiagnosed cases2,3. It was the fifth leading cause of death in 2023, claiming over 140,000 lives4. Globally, there are ~500 million COPD cases, causing ~3.5 million death in 20215.

The chronic disease nature of COPD significantly diminishes patients’ quality of life, restricting daily activities, requiring continuous treatment, and leading to physical, emotional, and social burdens that worsen as the disease progresses. Moreover, people with COPD may experience flare-ups (exacerbations) where symptoms suddenly become much worse, which leads to hospitalization, accelerated lung function loss, increased risk of death6,7. Within COPD, up to 40% of patients belong to a subgroup with elevated type 2 inflammation8. Patients in this subgroup (T2-high COPD) represent a more serious condition, facing up to 76% higher exacerbation risk, and 62% higher odds for lung function decline9,10.

Sources

  1. GOLD COPD Report (2025) — https://goldcopd.org/2025-gold-report/
  2. CDC: About COPD (n.d.) — https://www.cdc.gov/copd/about/index.html
  3. PubMed: Systemic inflammation in COPD (2014) — https://pubmed.ncbi.nlm.nih.gov/25126252/
  4. CDC Data Brief: COPD (2024) — https://www.cdc.gov/nchs/products/databriefs/db529.htm
  5. JAMA Network Open: COPD study (2023) — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812622
  6. Nature: COPD research article (2024) — https://www.nature.com/articles/s41533-024-00378-7
  7. PubMed: Emerging COPD evidence (2024) — https://pubmed.ncbi.nlm.nih.gov/38259591/
  8. PubMed: COPD outcomes study (2023) — https://pubmed.ncbi.nlm.nih.gov/37348121/
  9. PubMed: COPD management study (2017) — https://pubmed.ncbi.nlm.nih.gov/29153881/
  10. Respiratory Research: COPD mechanisms (2021) — https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01847-0

Asthma

Asthma is a widespread, serious and long-term respiratory disease characterized by airway inflammation, bronchoconstriction, and excessive mucus production, often triggered by allergens, respiratory infections, pollution, and irritants1. It leads to symptoms such as recurrent wheezing, chest tightness, coughing, and breathlessness1. In the U.S., approximately 24.9 million people, including 4.7 million children, are living with asthma in 2021 (about 7.7 percent of the population2). Globally, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths3.

As a chronic disease, asthma substantially reduces patients’ quality of life by limiting physical activity, disrupting sleep, and necessitating ongoing medication and self-management4. Exacerbations—acute flare-ups of symptoms—can lead to emergency visits, hospitalization, and even death4; for example, approximately 94,560 inpatient hospitalization and nearly 986,453 emergency department visits occurred in the U.S. in 2020. Asthma disease severity is largely driven by type 2 (T2) inflammation and cytokines like IL‑4, IL‑5, and IL‑13—patients with elevated T2 inflammation are associated with significantly increased asthma attacks, wheeze, ED visits, exacerbation rates, uncontrolled asthma, and lung function decline.

Sources

  1. Cleveland Clinic: Asthma (n.d.) — https://my.clevelandclinic.org/health/diseases/6424-asthma
  2. CDC: Preventing Chronic Disease – Asthma (2024) — https://www.cdc.gov/pcd/issues/2024/24_0005.htm
  3. WHO: Asthma Fact Sheet (n.d.) — https://www.who.int/news-room/fact-sheets/detail/asthma
  4. GINA: Global Initiative for Asthma – Summary Guide (2024) — https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf
  5. ScienceDirect: Asthma and Allergy Review (2013) — https://www.sciencedirect.com/science/article/abs/pii/S0091674913009196
  6. Clinical and Translational Allergy: Asthma study (2019) — https://ctajournal.biomedcentral.com/articles/10.1186/s13601-019-0282-7
  7. ScienceDirect: Asthma treatment outcomes (2016) — https://www.sciencedirect.com/science/article/abs/pii/S0091674916003791

CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-term condition where your sinuses stay inflamed for more than 12 weeks and soft, non-cancerous growths called nasal polyps develop inside your nose and sinuses1. These grape-like growths are caused by ongoing inflammation and can block your nasal passages, making it hard to breathe through your nose and causing a stuffy, congested feeling2. The main symptoms include persistent nasal congestion, runny nose, reduced or lost sense of smell and taste, facial pressure or pain, and thick mucus draining down your throat2. CRSwNP affects about 1-4% of the population1 and is more common in people aged 40-602, especially those who also have asthma1. The condition often occurs alongside other allergic diseases3, and people with Type 2 disorders are particularly prone to developing it1.

Sources

  1. Allergy & Asthma Network. “What is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)?” May 16, 2025. https://allergyasthmanetwork.org/health-a-z/chronic-rhinosinusitis-with-nasal-polyps-crswnp/
  2. American College of Allergy, Asthma & Immunology (ACAAI). “Chronic Rhinosinusitis With Nasal Polyps.” July 27, 2021. https://acaai.org/allergies/allergic-conditions/chronic-rhinosinusitis-with-nasal-polyps/
  3. EUFOREA (European Forum for Research and Education in Allergy and Airway Diseases). “Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).” April 8, 2025. https://www.euforea.eu/crswnp/
Linkedin-in

Jon Lieber

Chief Financial Officer

Jonathan I. Lieber, MBA, is Chief Financial Officer of Bambusa Therapeutics. Jonathan brings more than 30 years of financial, strategic, and business experience across the life sciences industry.

Jonathan joined Bambusa from Rallybio Corporation, where he has served as Chief Financial Officer since 2023. Previously, he served as Chief Financial Officer of Applied Genetic Technologies Corporation and as a Managing Director at Danforth Advisors, where he provided strategic and operational financial leadership to life sciences companies. Earlier in his career, Jonathan served as Chief Financial Officer of Histogenics Corporation, Metamark Genetics, Repligen Corporation, Xcellerex, and Altus Pharmaceuticals. He began his career in healthcare investment banking at Salomon Brothers/Salomon Smith Barney and Cowen and Company/SG Cowen.

Jonathan currently serves on the boards of directors of Decoy Therapeutics, MindWalk Holdings, and Zola Therapeutics. He holds a B.S. in Business Administration and Finance from Boston University and an MBA in Finance from New York University’s Leonard N. Stern School of Business.

Todd James

Executive Vice President, Chief Financial Officer

Todd R. James serves as Chief Financial Officer of Bambusa Therapeutics, where he leads the company’s finance organization, capital markets strategy, and investor relations.

Prior to joining Bambusa, Mr. James founded TRJ BioAdvisors, where he advised biotechnology CEOs and Boards on capital markets strategy, investor relations, corporate communications, and special situations including mergers and acquisitions, shareholder activism defense, and clinical data disclosures.

Previously, Mr. James served as Senior Vice President of Corporate Affairs and Investor Relations at Viridian Therapeutics. Earlier, he held leadership roles of increasing responsibility at Acceleron Pharma, where he was a member of the Executive Committee and built the company’s investor relations, corporate communications, and broader external stakeholder engagement functions. During his tenure, he supported multiple public equity financings totaling more than $1 billion prior to the company’s $11.5 billion acquisition by Merck.

Earlier in his career, Mr. James served as a Senior Vice President at The Trout Group / Trout Capital and began his career at Thomson Financial providing capital markets intelligence to publicly traded biotechnology companies.

Mr. James has been recognized multiple times by Institutional Investor as a member of the All-America Executive Team for excellence in biotechnology investor relations. He holds a B.A. in Economics with a concentration in Finance from Moravian University.

Jen Salstrom

Vice President, Clinical Development

Bio here.

BBT002

Type 2 (T2) inflammatory diseases are characterized by skewed T2 immune responses driven by T2 cytokines including IL-4, IL-13, and IL-5. In specifics, IL-4 and IL-13, acting through IL-4Rα, promote Th2 polarization, IgE production, barrier dysfunction, mucus hypersecretion, and tissue remodeling, while IL-5 sustains eosinophil maturation, survival, and effector damage. These cytokines drive T2 inflammation across the airways, skin, and gut, contributing to diseases such as chronic obstructive pulmonary disease (COPD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergy, chronic spontaneous urticaria (CSU), and eosinophilic esophagitis (EoE), and making them key therapeutic targets1. Dual targeting IL-4Rα and IL-5 offers advantages over single targeting of IL-4Rα or IL-5 or upstream alarmin proteins (e.g., TSLP, IL-33) by preventing escape (or “leakage”2) of the downstream T2 cytokines (IL-4, IL-13 and IL-5) and providing complete inhibition of the pathogenic inflammation.

BBT002 blocks the entire spectrum of Type 2 cytokines (IL-4, IL-13, and IL-5) while incorporating Fc mutations that eliminate unwanted effector functions and extend half-life for longer dosing intervals. The dual targeting design positions it to provide more comprehensive benefits over current single targeting therapies across T2 inflammatory diseases, particularly those with significant eosinophilic inflammation, while eliminating the risk of eosinophilia associated with anti-IL-4Rα monotherapy.

  1. Nature Reviews Immunology: Allergy and Immunology Study (2025) — https://www.nature.com/articles/s41423-025-01261-2
  2. Wiley Online Library: Allergy Journal Article (2023) — https://onlinelibrary.wiley.com/doi/full/10.1111/all.16537

BBT001

BBT001 is a bispecific IgG1 antibody for Type 2 inflammatory dermatological conditions. Using a 2+2 format, it simultaneously engages IL-4Rα and IL-31 to deliver faster and synergistic efficacy compared to existing treatments.

The drug incorporates Fc modifications that enhance FcRn affinity and extend half-life, enabling longer dosing intervals.

BBT001’s innovation addresses a critical treatment gap. While targeting IL4/13 tackles the fundamental Th2 inflammatory cascade, it does not effectively reduce IL-31 levels, providing only slow, moderate itch relief. This leaves patients trapped in the destructive “itch-scratch cycle” where continuous scratching compromises skin barrier function and perpetuates inflammation.

BBT001’s direct IL-31 targeting is designed to immediately affect sensory nerves, rapidly reducing itchiness while accelerating skin lesion improvement. This dual-pathway approach promises to break the itch-scratch cycle more effectively than single-target therapies, potentially transforming treatment for Type 2 inflammatory dermatological conditions.

Mike Malynn

Director, Finance

Mike Malynn is Director, Finance at Bambusa. Mike brings seven years of finance and operations experience scaling biotech companies and drives Bambusa’s financial strategy to support our mission of delivering transformative treatments. Prior to joining Bambusa, Mike led U.S. operations and supported portfolio companies from inception through seed stage as Finance Manager at Gordian Ventures. He was also the first finance employee at Silicon Therapeutics, where he built the finance function and helped drive the company’s acquisition by Roivant Sciences.

Based in Boston, Massachusetts, Mike holds a B.S.B.A in Business Economics from Suffolk University, graduating Summa Cum Laude.

Shaoyang Yeh, DPhil

Associate Director, CMC

Shaoyang Yeh, DPhil, is Associate Director of CMC at Bambusa Therapeutics. Shaoyang brings extensive process development and CMC experience from leadership roles at MabPlex USA (antibody drug conjugates), Emergent BioSolutions (Phase III vaccines), and BioLegend/Revvity (diagnostic antibodies and reagents). At MabPlex, he worked directly with clients on process design, technology transfer, and regulatory filings for novel biologic products.

Based in San Diego, Shaoyang holds bachelor’s degrees in Bioengineering and Biology from UC San Diego, a master’s in Biomedical Engineering from Cornell, and a DPhil in Engineering Science from Oxford, focusing on tissue engineering and bioprocessing.

Tracy Ji, MD

Director, Clinical Operations

Xiaoping (Tracy) Ji, MD is a Director, Clinical Operations at Bambusa. Leveraging over 19 years of clinical trial experience in her strategic leadership role, she previously served as Project Director at LabCorp, managing global Phase I-III trials across Australia, USA, and EU. Prior to LabCorp, Tracy worked with several global pharmaceutical companies including GSK, Novartis, Roche, and Eisai, gaining extensive knowledge in trial management from both sponsor and CRO perspectives.

 Based in Beijing, China, Tracy holds a Postgraduate Diploma in Public Health from the University of Auckland, New Zealand, complemented by a Bachelor of Clinical Medicine from Heilongjiang University of Chinese Medicine.

Wei Liang, PhD

Director, Development Sciences

Wei Liang, Ph.D., is the Director, Development Sciences at Bambusa and brings over 13 years of post-Ph.D. research and development experience across multiple disease areas to his role. Wei previously served as the Associate Director, R&D at Ansun Biopharma, where he led the cell therapy R&D programs and contributed to the development of a biologic drug candidate. Prior to that, he served as Associate Director I at BioDuro-Sundia, where he rebuilt and led its Oncology San Diego division.

Wei earned his B.S. from the University of Science and Technology of China and completed his Ph.D. at the City of Hope Comprehensive Cancer Center. He continued his research training with postdoctoral work at City of Hope and UC, San Diego.

Lisa Li, MD

Senior Director, Clinical Operations

Lisa Li is a Senior Director, Clinical Operations at Bambusa. Lisa brings extensive clinical operations expertise to her current role, with experience spanning a broad range of therapeutic areas, including infectious disease, dermatology, oncology, pain, rare disease, In addition to operational leadership, Lisa also contributed to corporate strategic initiatives, including supporting the sale of clinical assets during company restructuring at Vital Therapies.

Originally from Beijing, China, Lisa holds a medical degree and earned an MSc in Human Nutrition from the University of Glasgow. She is currently based in San Diego, California.

Jingjing Jiang, MD, PhD

Senior Director, Development Sciences

Dr. Jingjing Jiang is Senior Director of Development Sciences at Bambusa Therapeutics. With expertise in translational research and development sciences, she has a strong track record of building R&D teams, advancing therapeutic platforms, and bridging preclinical and clinical research. Jingjing has held roles at biotech companies of various sizes, including Poseida Therapeutics, contributing to innovative drug development across multiple therapeutic modalities.

Jingjing holds an M.D. from Zhejiang University and a Ph.D. in Biomedical Engineering from UC Irvine.

Melody Zhu, PhD

Vice President, Corporate Development and Strategy

Melody (Yun) Zhu, PhD, is the Vice President, Corporate Development & Strategy at Bambusa Therapeutics. Melody brings extensive cross-functional experience spanning R&D, business strategy, and external innovation across the pharmaceutical and biotech industries. Prior to joining Bambusa, Melody served as Director of External Innovations at BioNTech in Shanghai, where she led the search and evaluation of potential in-licensing opportunities, including assets from Duality and MediLink. Melody also held leadership roles at Sanofi driving portfolio development across Immunology & Inflammation and Oncology, contributing to programs including Dupixent and Itepekimab. She began her career in strategy consulting with Boston Consulting Group (BCG) and IQVIA.

Originally from China, Melody earned her Ph.D. in Biochemistry from The Chinese University of Hong Kong, and her B.S. in Biochemistry from Nanjing University.

Wei Lin, MD ScM

Vice President, Clinical Development

Wei Lin, MD, ScM, is Vice President of Clinical Development at Bambusa. Wei brings extensive experience in clinical development across the I&I therapeutic area. Prior to joining Bambusa, she served as Senior Director and Clinical Lead at Everest Medicines, where she was responsible for the global development of a BTK inhibitor in glomerular diseases. Previously, she was Director and Clinical Lead at Pfizer, overseeing rheumatology and inflammatory bowel disease (IBD) programs. There, she successfully led China’s Phase 3 development of tofacitinib for psoriatic arthritis and ankylosing spondylitis, resulting in NDA approvals. Her team also managed multiple clinical programs in systemic lupus erythematosus, ulcerative colitis, systemic juvenile idiopathic arthritis, and dermatomyositis in China.

Originally from Xiamen, China, Wei earned her MD from Peking University and holds a ScM in Epidemiology from Johns Hopkins University.

Wenbing Hu, PhD

Vice President, Head of CMC

Wenbing Hu, PhD, is Vice President and Head of CMC at Bambusa Therapeutics. Wenbing brings extensive expertise in biologics CMC development and manufacturing, previously serving as Senior Director of Pharmaceutical Development at Ansun Biopharma, where he led CMC activities for late-stage clinical trials. Prior to Ansun, Wenbing held leadership roles at Sorrento Therapeutics, overseeing analytical development, quality control, and formulation, and successfully advanced multiple antibody and mRNA projects through clinical phases. His deep experience spans from early-stage CMC development to global regulatory filings and GMP manufacturing operations.

Based in San Diego, California, Wenbing earned his PhD in Analytical Chemistry from the Institute of Chemistry, Chinese Academy of Sciences.

Crystal MacKay

Chief Operating Officer

Crystal MacKay is the Chief Operating Officer at Bambusa. Crystal brings extensive healthcare experience to her current role, having previously served as a Director of Healthcare Investment Banking at BTIG, where she was responsible for transaction execution in the Life Science & Diagnostic Tools and Medical Technology sectors. Crystal built operational expertise through leadership roles at innovative healthcare companies, including Oxford Immunotec, where she played a key role in strategic initiatives during the company’s transition, Strata Pathology Services, and Calloway Laboratories, where she served on the Board of Directors. 

Based in Boston, Massachusetts, Crystal holds a Bachelor of Arts in Business Communications from the University of Massachusetts and maintains securities licenses including SIE, Series 79, and Series 63.

Thang Ho, PhD

Co-Founder and Chief Development Officer

Thang Ho, Ph.D. is the Co-Founder and Chief Development Officer at Bambusa, where he leads an integrated team spanning preclinical research, translational medicine, toxicology, and clinical pharmacology while playing a critical role in shaping the company’s strategy across U.S. and global programs. Prior to Bambusa, Thang served as Director of Clinical Pharmacology and Pharmacometrics at BioNTech, leading clinical pharmacology strategies for innovative programs including cell and gene therapies and immuno-oncology agents. His career also includes scientific roles at Takeda, CytomX, and Vertex Pharmaceuticals.

Trained as a systems pharmacologist and engineer, Thang holds a Ph.D. in Chemical Engineering from the University of Pittsburgh, and earned his B.S. and M.S. in Chemical Engineering from the University of Arkansas. Originally from Da Nang, Viet Nam, Thang is based in Boston, Massachusetts.

Shanshan Xu, MD, PhD

Founder and Chief Executive Officer

Shanshan Xu, MD, PhD, is the Founder and Chief Executive Officer of Bambusa. Shanshan founded Bambusa with a belief that the I&I field is long overdue for innovative approaches and transformative cutting-edge solutions.

Prior to founding Bambusa, Shanshan served as Head of Global External Innovations at BioNTech, where she and her team sourced and executed 13 strategic partnerships and acquisitions to expand BNT’s pipeline. Her most notable accomplishment was identifying and acquiring Biotheus, which brought BNT327 (now partnered with BMS in a deal valued up to $11.1B). In addition, she identified the I&I molecules within Biotheus that ultimately became the foundation of Bambusa. Her portfolio also included the Duality, MediLink and OncoC4 partnerships, Tier 1 oncology programs. Before joining BioNTech in 2020, Shanshan worked on Wall Street as a Research Analyst.

Originally from Harbin, China, Shanshan spent almost half of her life in Mainland China, where she received her medical degree. She also holds a Ph.D. from UC-Irvine and an MBA from MIT.